The estimated Net Worth of Keith Orford is at least 1.48 百万$ dollars as of 10 November 2021. Mr. Orford owns over 78,190 units of Calithera Biosciences Inc stock worth over 3,305$ and over the last 9 years he sold CALA stock worth over 236,447$. In addition, he makes 1,241,570$ as Chief Medical Officer at Calithera Biosciences Inc.
Sign up
Mr. Orford CALA stock SEC Form 4 insiders trading
Keith has made over 13 trades of the Calithera Biosciences Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 78,190 units of CALA stock worth 68,025$ on 10 November 2021.
The largest trade he's ever made was selling 78,190 units of Calithera Biosciences Inc stock on 10 November 2021 worth over 68,025$. On average, Keith trades about 6,609 units every 72 days since 2016. As of 10 November 2021 he still owns at least 66,094 units of Calithera Biosciences Inc stock.
You can see the complete history of Mr. Orford stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Keith Orford biography
Keith Orford M.D., Ph.D. serves as Chief Medical Officer of the Company. Dr. Orford joined Calithera in January 2015 and currently serves as our Chief Medical Officer. Prior to joining Calithera in January 2015, Dr. Orford was the Clinical Development Lead in the Immuno-Oncology and Combinations Development Performance Unit at GlaxoSmithKline (GSK) where he oversaw the clinical activities on multiple early stage clinical trials with targeted agents and novel immune-based therapies. Prior to GSK, Dr. Orford was at Merck, where he worked on early clinical development programs across oncology and other therapeutic areas. Previously, Dr. Orford was a Research Fellow and Instructor at Massachusetts General Hospital (MGH) and Harvard Medical School (HMS) where he completed clinical training in Internal Medicine as well as postdoctoral work studying the epigenetic regulation of hematopoietic and embryonic stem cell differentiation. Dr. Orford received his undergraduate, M.D. and Ph.D. degrees from Georgetown University.
What is the salary of Keith Orford?
As the Chief Medical Officer of Calithera Biosciences Inc, the total compensation of Keith Orford at Calithera Biosciences Inc is 1,241,570$. There are 2 executives at Calithera Biosciences Inc getting paid more, with Susan Molineaux having the highest compensation of 2,209,840$.
How old is Keith Orford?
Keith Orford is 48, he's been the Chief Medical Officer of Calithera Biosciences Inc since 2018. There are 16 older and 6 younger executives at Calithera Biosciences Inc. The oldest executive at Calithera Biosciences Inc is H. Ward Wolff, 71, who is the Independent Director.
What's Keith Orford's mailing address?
Keith's mailing address filed with the SEC is C/O CALITHERA BIOSCIENCES, INC., 343 OYSTER POINT BLVD. #200, SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at Calithera Biosciences Inc
Over the last 10 years, insiders at Calithera Biosciences Inc have traded over 23,150,153$ worth of Calithera Biosciences Inc stock and bought 7,859,025 units worth 49,155,939$ . The most active insiders traders include Partners L P/Ilbiotechnolog...、Capital Partners Gp, L.L.C....、Deepika Pakianathan. On average, Calithera Biosciences Inc executives and independent directors trade stock every 43 days with the average trade being worth of 8,053$. The most recent stock trade was executed by Deepika Pakianathan on 27 January 2023, trading 121,333 units of CALA stock currently worth 47,320$.
What does Calithera Biosciences Inc do?
calithera is focused on discovering and developing first-in-class small molecule drugs that slow tumor growth through controlling key metabolic pathways in the tumor and immune cells. tumor metabolism and tumor immunology are promising new interrelated fields for cancer drug discovery. recent clinical successes have demonstrated the potential to slow abnormal cell growth and create fundamentally new therapies for cancer patients. our investigational onco-metabolism medicines take advantage of the different metabolic requirements of tumor cells and cancer-fighting immune cells. calithera’s discovery and development efforts are focused on solid tumors for which new treatments are urgently needed. we are currently developing our lead candidate in phase 2 trials in patients with renal cell carcinoma, triple negative breast cancer. targeting cancer, differently. our onco-metabolism approach brings an enhanced perspective to cancer.
What does Calithera Biosciences Inc's logo look like?
Complete history of Mr. Orford stock trades at Calithera Biosciences Inc
Calithera Biosciences Inc executives and stock owners
Calithera Biosciences Inc executives and other stock owners filed with the SEC include:
-
Susan Molineaux,
President, Chief Executive Officer, Co-Founder, Director -
Sumita Ray,
Senior Vice President, Chief Compliance Officer, General Counsel -
Keith Orford,
Chief Medical Officer -
Curtis Hecht,
Chief Business Officer -
Dr. Susan M. Molineaux Ph.D.,
Founder, CEO, Pres & Director -
Christopher Molineaux,
Senior Vice President - Development -
Eric Sjogren,
Senior Vice President - Drug Discovery -
Deepa Pakianathan,
Lead Independent Director -
H. Ward Wolff,
Independent Director -
Jean George,
Independent Director -
Sunil Agarwal,
Independent Director -
Suzy Jones,
Independent Director -
Blake Wise,
Independent Director -
Jonathan Drachman,
Independent Director -
Scott Garland,
Independent Director -
Jennifer McNealey,
Vice President, Investor Relations and Strategy -
Francesco Parlati,
Vice President - Research -
Stephanie Wong,
Vice President - Finance, Secretary -
Dr. Allison Dillon Ph.D.,
Sr. VP of Commercial & Portfolio Strategy -
Dr. Susan B. Demo Ph.D.,
Sr. VP of R&D Operations -
Matthew Gross,
Head of Bus. Devel. -
Dr. Emil T. Kuriakose M.D.,
Chief Medical Officer -
Frank Parlati,
Sr. VP of Research -
Dr. Christopher J. Molineaux Ph.D.,
Sr. VP of Devel. -
Dr. Eric B. Sjogren,
Sr. VP of Drug Discovery -
Sumita Ray J.D.,
Chief Legal & Admin. Officer -
Stephanie Wong,
CFO & Sec. -
Capital Partners Gp, L.L.C....,
-
William D. Waddill,
SENIOR VP & CFO -
Mark K Bennett,
SR. VP, RESEARCH -
Venture Partners Ix Lp Morg...,
10% owner -
Management Partners Viii, L...,
-
Technology Ventures Viii Lp...,
-
Ralph E Christoffersen,
Director -
Partners L P/Ilbiotechnolog...,
-
Pharmaceutical Co Ltd Taked...,
-
Deepika Pakianathan,
Director -
Emil Kuriakose,
CHIEF MEDICAL OFFICER